Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321120 | 0.93 | TAAR1 (0.45) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL4717912 | 0.90 | TAAR1 (0.49) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL6321115 | 0.87 | TAAR1 (0.46) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL4721369 | 0.78 | TAAR1 (0.45) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL4717265 | 0.78 | TAAR1 (0.50) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL4722227 | 0.77 | TAAR1 (0.47) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL4720980 | 0.77 | TAAR1 (0.47) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL4717699 | 0.77 | ADRA2C (0.46) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL4717899 | 0.77 | TAAR1 (0.49) | TAAR1ADRA2AADRA2BADRA2CMAPK1 | |
| SCHEMBL28758566 | 0.77 | TAAR1 (0.46) | TAAR1ADRA2AADRA2BADRA2CMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660484-B1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | EP | disclosed |
| CN-100378097-C | Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| CN-1784397-A | Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists | HOFFMANN LA ROCHE (CH) | 2006-06-07 | — | — | CN | disclosed |
| EP-1660484-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPHA-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-6979696-B2 | Method for detecting a gram-negative bacterial autoinducer molecule | ROCHE PALO ALTO LLC (US) | 2005-12-27 | — | — | US | disclosed |
| WO-2004099189-A1 | METHYL INDOLES AND METHYL PYRROLOPYRIDINES AS ALPH-1 ADRENERGIC AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-18 | — | — | WO | disclosed |
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ROCHE PALO ALTO LLC | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224973-A1 | Substituted indoles as alpha-1 agonists | ADRA1A, ADRB1, ADRA1D | TAAR1 39/4885ADRA2A 5/4885ADRA2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.